Surgical Site Infections (SSIs) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Surgical Site Infections (SSIs) are a devastating and common complication of hospitalization, occurring in 2% to 5% of patients undergoing surgery in the United States. SSIs lead to increased duration of hospitalization, cost, and risk of death. Each SSI leads to more than one week of additional postoperative hospital days. Most SSIs that do not involve implants are diagnosed within three weeks of surgery. SSIs are classified as either incisional or organ/ space. Incisional SSIs are further classified into superficial or deep. Organ/space SSIs include infections in tissue deep to the fascia that was opened or manipulated during surgery. For all classifications, the infection can occur within 30 days after the operation if no implant was placed or within 90 days if an implant was placed and the infection is related to the incision. SSI will occur due to a complex relationship between microbial characteristics, host characteristics, and wound elements.

 

In the USA, ~200,000 to 300,000 Surgical Site Infections (SSIs) are reported each year. Staphylococcus aureus is the most common cause of SSI, occurring in hospitals in 20 to 25% of SSIs.

 

The competitive landscape of Surgical Site Infections (SSIs) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights on Surgical Site Infections (SSIs) across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Surgical Site Infections (SSIs) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Surgical Site Infections (SSIs) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          PLEX₁₀₀            PolyPid Ltd.      Phase 3

2          70% v/v Isopropyl Alcohol Surgical Solution        Zurex Pharma, Inc.            Phase 3

3          Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic            Professional Disposables International, Inc.        Phase 3

4          DFA-02 Antibiotic Gel    Dr. Reddy's Laboratories Limited            Phase 2

5          gentamicin-collagen sponge dipped        Innocoll Pharmaceuticals            Phase 3

6          Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD  HK Surgical, Inc.     Phase 3

7          2% chlorhexidine gluconate cloths          Sage Products, Inc.            Phase 3

8          XF-73   Destiny Pharma Plc       Phase 2

9          E-101   Excited States, LLC       Phase 3

10        methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation          Ondine Biomedical Inc.  Phase 2

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypoglycemia and severe
Read more